Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Agios Pharmaceuticals (AGIO)

Agios Pharmaceuticals (AGIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,067,073
  • Shares Outstanding, K 57,030
  • Annual Sales, $ 26,820 K
  • Annual Income, $ -352,090 K
  • EBIT $ -407 M
  • EBITDA $ -405 M
  • 60-Month Beta 0.75
  • Price/Sales 117.79
  • Price/Cash Flow N/A
  • Price/Book 1.94

Options Overview Details

View History
  • Implied Volatility 54.90% ( +5.29%)
  • Historical Volatility 52.05%
  • IV Percentile 79%
  • IV Rank 57.71%
  • IV High 80.83% on 05/31/24
  • IV Low 19.51% on 05/16/24
  • Put/Call Vol Ratio 4.32
  • Today's Volume 804
  • Volume Avg (30-Day) 308
  • Put/Call OI Ratio 1.07
  • Today's Open Interest 13,557
  • Open Int (30-Day) 12,238

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.71
  • Number of Estimates 7
  • High Estimate -1.55
  • Low Estimate -1.86
  • Prior Year -1.72
  • Growth Rate Est. (year over year) +0.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.96 +28.17%
on 10/16/24
62.58 -14.06%
on 11/11/24
+11.74 (+27.93%)
since 10/15/24
3-Month
39.94 +34.65%
on 10/07/24
62.58 -14.06%
on 11/11/24
+8.87 (+19.75%)
since 08/15/24
52-Week
20.96 +156.58%
on 01/19/24
62.58 -14.06%
on 11/11/24
+31.31 (+139.34%)
since 11/15/23

Most Recent Stories

More News
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition

AGIO : 53.78 (-2.92%)
Agios Pharmaceuticals: Q3 Earnings Snapshot

Agios Pharmaceuticals: Q3 Earnings Snapshot

AGIO : 53.78 (-2.92%)
Agios Reports Business Highlights and Third Quarter 2024 Financial Results

AGIO : 53.78 (-2.92%)
Agios Completes Enrollment of Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease

AGIO : 53.78 (-2.92%)
Agios to Webcast Conference Call of Third Quarter 2024 Financial Results on October 31, 2024

AGIO : 53.78 (-2.92%)
Do Options Traders Know Something About Agios (AGIO) Stock We Don't?

Investors in Agios Pharmaceuticals, Inc. AGIO need to pay close attention to the stock based on moves in the options market lately. That is because the Dec. 20, 2024 $17.50 Put had some of the highest...

AGIO : 53.78 (-2.92%)
Agios Pharmaceuticals: Q2 Earnings Snapshot

Agios Pharmaceuticals: Q2 Earnings Snapshot

AGIO : 53.78 (-2.92%)
Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024

Stocks that traded heavily or had substantial price changes on Tuesday: Insmed, Agios rise; DraftKings, Atlantica fall

CORT : 51.83 (-5.40%)
ET : 17.29 (+0.82%)
USM : 61.54 (-0.13%)
AY : 22.11 (+0.05%)
DKNG : 39.84 (-3.16%)
AGIO : 53.78 (-2.92%)
INSM : 66.29 (-6.97%)
Agios Pharmaceuticals: Q1 Earnings Snapshot

Agios Pharmaceuticals: Q1 Earnings Snapshot

AGIO : 53.78 (-2.92%)
Agios Pharmaceuticals: Q3 Earnings Snapshot

Agios Pharmaceuticals: Q3 Earnings Snapshot

AGIO : 53.78 (-2.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on development of treatments for rare genetic metabolic disorders, a subset of orphan genetic metabolic diseases.

See More

Key Turning Points

3rd Resistance Point 58.32
2nd Resistance Point 56.99
1st Resistance Point 55.39
Last Price 53.78
1st Support Level 52.46
2nd Support Level 51.13
3rd Support Level 49.53

See More

52-Week High 62.58
Last Price 53.78
Fibonacci 61.8% 46.68
Fibonacci 50% 41.77
Fibonacci 38.2% 36.86
52-Week Low 20.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar